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Abstract
Background: Annual surveillance (with thyroid function testing) is widely recommended for the
long-term follow-up of treated hypothyroid patients. It is based largely on consensus opinion and
there is limited evidence to support the frequency of monitoring. The majority of patients in our
hospital based thyroid register are on 18 monthly follow-up.
Methods: We carried out a retrospective analysis to see if there is evidence to support more
frequent testing. We used a logistic regression model to assess whether any baseline characteristics
could be applied to predict an abnormal test.
Results: We identified 2,125 patients with a minimum of 10 years follow-up (89% female, 65%
autoimmune hypothyroidism, and mean age at registration 51 years). There were 2 groups: 1182
(56%) had been allocated to 18 monthly follow-up and the rest had annual surveillance. The groups
were well matched at baseline. Overall, during follow-up the 12 monthly group had more abnormal
tests requiring dose adjustment. However, on logistic regression analysis, people aged less than 60
years, individuals taking < 150 µg thyroxine per day and people on 18 monthly follow-up had less
abnormal tests.
Conclusion: 18 monthly surveillance may be adequate in the long term follow-up of hypothyroid
patients less than 60 years of age on a stable thyroxine dose of 100–150 µg/day where there are
robust follow-up mechanisms in place. Implementing this strategy has potential for cost saving.
Background
Hypothyroidism is usually due to primary thyroid failure
secondary to chronic autoimmune thyroiditis (Hashim-
oto's disease) or destructive therapy (radioactive iodine or
thyroidectomy). In the United Kingdom the prevalence of
overt hypothyroidism in women is at least 1.4 to 1.9%
compared to less than 1% in men [1], and increases with
age [2]. Levothyroxine is the standard replacement ther-
apy and treatment is life long, with the aim of restoring
patients to a euthyroid state and normalising thyroid
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stimulating hormone (TSH) concentration. Though the
treatment of hypothyroidism is straightforward, data
from several studies [3-5] show that only around 60% of
patients on thyroxine replacement have normal TSH lev-
els. Thyroxine over replacement is associated with
increased risk of atrial fibrillation [6] and reduction in
bone mass in postmenopausal women [7]. In addition a
raised TSH level is associated with an unfavourable lipid
profile [4,8].
Hence periodic monitoring of thyroid function tests
(TFTs) is essential in the management of patients to judge
the response to therapy, patient compliance, and to adjust
doses in relation to advancing age. Annual TFT surveil-
lance is widely recommended [9-11]. In the UK, the Gen-
eral Practitioner (GP) contract [12] effective from April
2004, which financially rewards primary care practices,
recommends that patients with hypothyroidism on thy-
roxine, should have thyroid function tests recorded at
least every 15 months. The recommended frequency of
testing is based largely on consensus, and there is limited
evidence to support this. The majority of patients cur-
rently followed up in our hospital based thyroid register
are on 18 monthly follow-up. We undertook a retrospec-
tive study to see if there is evidence to support more fre-
quent testing.
Methods
Grampian Automated Thyroid Register (previously
known as Scottish Automated Follow-up Register) has
provided follow-up facilities for patients with thyroid dis-
ease since 1967, as a joint venture between hospital and
primary care. Currently around 20,000 patients are regis-
tered on the database. Patients are recalled at a pre-set fol-
low-up interval for TFTs and review by the primary care
staff, who provide information on clinical status. The
results are reviewed centrally, and if satisfactory, the com-
puter automatically generates a routine recall. If abnor-
mal, the result is reviewed by a thyroid specialist who may
recommend a dose change and/or an early review. Written
instructions are sent to the GP, reducing the number of
patients with abnormal tests requiring review at a hospital
based thyroid clinic. After an appropriate intervention,
when TFTs are satisfactory, individuals are returned to
routine review at the pre-set interval. If they fail to turn up
for review, a reminder is sent at 3 and 6 months. Deaths
are notified to the thyroid register.
We retrospectively identified hypothyroid patients on thy-
roxine who had a minimum of 10 years of follow-up on
the register. Only patients on 12 monthly and 18 monthly
follow-up plans were evaluated. As there were no set
guidelines for entering patients on the register, patients
were allocated to these follow-up intervals by clinicians
on a non-selective basis. We excluded patients who hadn't
returned for follow-up for more than 30 months (patients
who may have moved away from the region or were non-
compliant). Patients with drug-induced hypothyroidism
and 11 individuals with inadequate follow-up data were
also excluded from the study. The registration details
included age, aetiology of hypothyroidism and thyroxine
dose at registration. Follow-up information regarding the
number of reviews, defaults, changes in thyroxine dose or
follow-up interval and the results of the thyroid test at
each review was summarised from the database. TFTs
undertaken during follow-up were interpreted as hyper-
thyroid when TSH was suppressed (<0.01 mU/L) and
other thyroid hormones were elevated. An elevated TSH
(>4 mU/L) with or without a low thyroid hormone con-
centration was described as a hypothyroid test. The
method used for thyroid function testing varied during
the study period. Radio-immuno assay (RIA) was used up
to1995 (reference range: total T4 70–150 nmol/L, TSH
0.35–3.3 mU/L). From 1995 onwards automated immu-
noassay was used (Bayer diagnostics, reference range: FT4
10–25 pmol/L, TSH 0.35–3.3 mU/L). Data were ano-
nymised and permission was not required from the Gram-
pian Regional Ethics Committee to carry out this research.
Statistical methods
Data were analysed using Student's t-tests, Mann Whitney
and chi squared tests as appropriate. To explore the differ-
ences in abnormal tests between the follow-up plan logis-
tic regression was used. Covariates adjusted for were
gender, autoimmune hypothyroidism (yes or no), age at
registration (<25 years, 25 to 60 years, >60 years), thyrox-
ine dose at registration (<100 µg, 100 to 150 µg, >150 µg),
thyroid follow-up plan (12 monthly or 18 monthly) and
duration of follow-up in years. All analyses were carried
out in SPSS.
Results
Patient demographics
2,125 patients satisfied the inclusion criteria and the
majority (89%) were female. The mean age at registration
was 50.9 (standard deviation, SD, 13.3 years). The major-
ity (65%) had developed spontaneous (autoimmune)
hypothyroidism. Other causes included post radioiodine
treatment (23.0%), post surgery (6.6%), thyroiditis
(0.7%), and unavailable in the rest (4.7%). 1182 (55.6%)
were on 18 monthly follow-up and the rest had annual
surveillance. There was no significant difference between
the groups in relation to the baseline characteristics age,
sex and thyroxine dose (Table 1). A slightly higher propor-
tion of patients on 18 monthly follow-up (68% versus
62%) had autoimmune hypothyroidism (p < 0.01).
Follow-up
The average duration of follow-up was 16.2 (SD 4.5) years
(range 10–30). Comparisons between the two groups areBMC Endocrine Disorders 2007, 7:4 http://www.biomedcentral.com/1472-6823/7/4
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summarised in Table 2. As expected the 12 monthly fol-
low-up group required more reviews. Both groups were
largely compliant with follow-up, with more than 90%
attending a regular review as scheduled. Only a small
minority defaulted and had late reviews. A slightly higher
proportion of individuals in the 18 monthly group
required a review earlier than scheduled (usually at 6
months) compared to the 12 monthly group (6.2% vs
5.0%). The 12 monthly group had significantly more thy-
roid function tests compared to the 18 monthly group
(16,700 vs 14,526, p < 0.01) during follow-up.
Thyroxine dose changes
The mean thyroxine dose at the time of registration was
131.2 (SD 42.4) µg per day (range 25–300) and around
80% were on 100–150 µg of thyroxine per day. The mean
thyroxine dose at last/final review was 127.4 (SD 35.5) µg
(median 125, range 25–300). During follow-up, thyrox-
ine dose remained unchanged in 35.4%, and a further
31% and 21% of cases required a dose alteration of 25 µg
and 50 µg respectively during long term surveillance. Indi-
viduals taking 100–150 µg of thyroxine at registration had
fewer dose changes compared to the rest (40.5% vs
14.7%, p < 0.01). Only 62.7% on 18 monthly follow-up
required a dose change as opposed to 66.9% on annual
surveillance (p < 0.05).
Outcomes
Abnormal test results were defined as both hyperthyroid
and hypothyroid results. Seventy three percent on 18
monthly follow-up had at least one abnormal test during
long term follow-up as compared to 81% on annual sur-
veillance (p < 0.01). We used a logistic regression model
to assess if any baseline characteristics could be applied to
predict an abnormal test. The results are summarised in
Table 3. Older patients (aged >60 years) at registration
were more likely to have an abnormal test during follow-
up (odds ratio 1.36, 95% CI 1.07–1.73, P < 0.01). In rela-
tion to thyroid screening interval, the 18 monthly group
was less likely to have an abnormal test compared to the
12 monthly group (odds ratio 0.66, 95% CI 0.53–0.81, P
< 0.01). There was no interaction between the sub-group
variables and the screening interval. In addition, there was
no difference in mortality between the 2 groups.
Discussion
It is universally accepted that patients on thyroxine
replacement should have regular clinical and biochemical
surveillance to ensure compliance and adjust doses in
relation to changing requirements. However the ideal
screening interval has not been ascertained and there are
no published studies on the appropriate frequency of fol-
low-up. Surveillance by annual TFT is recommended by
most of the published thyroid guidelines [9-11]. The rec-
ommendations are largely based on consensus, and there
is limited evidence to support this practice. Vanderpump
et al [9] recommended further audit/study to clarify some
Table 3: Predictors of abnormal result
Baseline Characteristics Odds 
ratio
95% confidence 
interval
P value
Male 0.81 (0.59, 1.13) 0.21
Autoimmune hypothyroidism 0.98 (0.79, 1.22) 0.86
*Age at registration:
< 25 yrs 0.96 (0.54, 1.70) 0.96
> 60 yrs 1.36 (1.07, 1.73) 0.01
+Thyroxine dose at 
registration
<100 µg 1.34 (0.86, 2.09) 0.18
>150 µg 1.36 (0.98, 1.90) 0.07
Thyroid FU plan
18 monthly interval 0.66 (0.53, 0.81) <0.001
*Reference category: 25 to 60 years; +Reference category: 100 to 150 
µg
Table 1: Comparison of baseline characteristics between the groups
Baseline characteristics 12 monthly FU (n = 943) 18 monthly FU (n = 1182)
Age years mean (SD) 50.2 (13.9) 51.6 (12.8)
Thyroxine dose at registration (µg/day) mean (SD) 131.8 (41.4) 130.7 (43.1)
Age < 60 years (n = 1556) 73.4% 73.1%
Female (n = 1892) 90.3% 88.0%
Autoimmune hypothyroidism (n = 1384) 61.6% 67.9%
Mean duration of follow-up (years) mean (SD) 16.5 (4.6) 15.6 (4.4)
Table 2: Comparison of follow-up data between the groups
Follow-up data 12 monthly 
(n = 943)
18 monthly 
(n = 1182)
Total number of reviews 15,191 13,864
Percentage of early reviews 5% 6.2%
Percentage of late reviews 4.4% 2.4%
Percentage of routine reviews 90.6% 91.4%
Total number of tests 16,700 14,526
Average number of tests per 
person
17.7 12.3
Percentage of patients with at 
least one abnormal test during 
follow-up
81% 73%BMC Endocrine Disorders 2007, 7:4 http://www.biomedcentral.com/1472-6823/7/4
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of the uncertainties in the follow-up of hypothyroid
patients.
Grampian Automated Thyroid Register (GAFUR) was
established in 1967 [13], and is one of the oldest thyroid
registers in the world. Thyroid registers improve records,
ensure regular reviews, and promote early detection of
changes in the patient's clinical status. Thyroid registers
have proved to be beneficial in the long-term follow-up of
patients with thyroid dysfunction. They are cost-effective
[14] and achieve better biochemical control [15] in com-
parison to conventional follow-up. From our thyroid reg-
ister we were able to identify a large cohort of hypothyroid
patients on thyroxine with a minimum of 10 years of fol-
low-up. As expected the majority of patients were women
who had developed spontaneous hypothyroidism. As
there were no set guidelines, individuals were allocated to
either follow-up plan by the referring physician on a non-
selective basis. The baseline characteristics were well
matched and there did not appear to be any bias in rela-
tion to allocation to either group. The system of recall and
follow-up was well managed through good co-operation
and links between primary care and GAFUR. Individuals
in both the groups were compliant with follow-up
arrangements. Similar benefits of thyroid registers in
maintaining long term surveillance with minimal defaults
was reported by Jung et al. in 1991[16].
During follow-up thyroid function tests were undertaken
at each review appointment and 18 monthly follow-up
was not associated with an increase in adverse outcomes.
On the other hand, patients on annual surveillance were
more likely to have an abnormal test. Both the groups
were well matched at baseline (table.1) in relation to age
and sex distribution, thyroxine dose and duration of fol-
low-up, and we cannot readily account for the difference
in outcome. One possible explanation could be physician
bias at the time of registration. There were no set guide-
lines or criteria and it is possible that there was physician
bias while allocating individuals to annual screening tak-
ing into account factors such as compliance. It is also
likely that more frequent testing will find more abnormal
results. Another conclusion that can be drawn is that
annual surveillance should be recommended as there was
an increased chance of detecting an abnormal result. This
approach may however lead to unnecessary tests in some
individuals as thyroxine dose remained unchanged in
35% of patients during long term follow-up. On the other
hand, although 18 monthly surveillance cannot be
applied universally, it may be an option in individuals
whose thyroxine requirement is less likely to change or
have less abnormal tests during follow-up. We undertook
further sub-group analysis to identify individuals who
may be suitable for less frequent testing.
Patients aged over 60 years at the time of registration were
more likely to have an abnormal test during follow-up.
This may be due to decreased thyroxine requirements with
increasing age. This has been reported in previous studies
[17,18] and probably reflects the progressive decrease in
thyroxine degradation rate that occurs with advancing
age. The fall in thyroxine requirement with age also corre-
sponds to the loss of lean body mass [19]. Hence people
aged over 60 years require annual surveillance.
Individuals taking 100–150 µg/day required fewer dose
changes during long term follow-up compared to the rest.
We would recommend annual testing in individuals who
are on either <100 or >150 µg of thyroxine per day. Once
established on the appropriate dose of thyroxine, follow-
up interval can be extended to 18 months in individuals
aged less than 60 years. There were insufficient patients on
the register with a regular follow-up interval of two years
to evaluate even less frequent monitoring.
Individuals on annual surveillance had more frequent
reviews and required more TFTs compared to the 18
monthly group, and this will have cost implications. The
Grampian automated thyroid register currently has over
10,000 registered hypothyroid patients, and the majority
are being followed-up 18 monthly. Allocating everyone to
annual follow up would mean an extra 3,000 thyroid tests
per year. A thyroid function test costs around £15 for the
NHS (personal communication with Dr Heather Watson,
clinical biochemistry, NHS Grampian on 24/04/06). This
would amount to an extra spending of around £45,000
per year without taking into account the cost of additional
administrative time for GAFUR and primary care, and
inconvenience to the patient. Our study has shown that
18 monthly follow-up may be adequate in the majority of
patients under 60 years of age on a stable thyroxine dose
of 100–150 µg/day. Implementing these recommenda-
tions has potential benefits in terms of savings and reduc-
tion in the workload.
The Grampian automated thyroid register was set up in
the late 1960s and traditionally TSH and FT4 estimations
were undertaken. The recently published UK guidelines
[20] on the use of thyroid function tests recommend TSH
estimation alone in the long-term follow-up of treated
hypothyroid patients. We are considering changing our
practice to achieve additional cost savings in relation to
thyroid tests.
Conclusion
Treated hypothyroid patients require regular clinical and
biochemical surveillance. Annual surveillance is currently
recommended with no evidence to support this practice.
Our study has shown that 18 monthly surveillance may be
adequate in the long term follow-up of patients less thanPublish with BioMed Central    and   every 
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60 years of age on a stable thyroxine dose of 100–150 µg/
day. Implementing this strategy has potential for cost sav-
ing and reduction of workload in health services.
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